← back to picks

Founded 1931 · HQ Mannheim, DE EUR reporting (IFRS) Synthetic credit Aaa/AAA · net cash +€151M Valuation 2026-05-25 FCFF DCF · 1000-iter MC v3 · Dark

Specialty franchise at a discounted ord price · +43.8% upside from €30

β triangulated · BUY on MoS +43.8%

DCF lands at €43.15/share vs Xetra ord €30.00 — a 43.8% upside with 0.0% of Monte Carlo paths printing below today's price. World's #1 INDEPENDENT lubricants, 24-year dividend streak, net cash +€151M, family-controlled (Fuchs 59% of voting ord) and currently trading 25% BELOW the FPE3 preference line.

Sector Specialty chemicals · #1 INDEPENDENT lubricants Geo 🇩🇪 20% · 🇺🇸 17% · 🇨🇳 16% MC σ ±€4.20 · p5 €40 / p95 €54 Governance Fuchs family 59% voting · 0% haircut (ord) Quality Aaa synth · net cash +€151M · 24y div streak

Intrinsic / share

€43.15

no gov haircut · ord vote

Market / share

€30.00

FPE.DE · Xetra ord

Margin of safety

+43.8%

vs intrinsic

Enterprise value

€5.51B

62.9% terminal

Cost of equity / debt

6.33 / 1.96%

β 0.77 · CRP 0.87%

Terminal ROIC / g

12.88 / 2.0%

spread ~1088bp

What it sells, where it sells

Customer-sector mix — FY25 revenue €3,563M

Automotive (On-Hwy + Components)17% engine-oil exposure to EV transition + 15% vehicle components 32%

Industrial (Primary + Equipment)19% + 9% · cyclical tie to mining, energy, heavy machinery 28%

Aftermarket & TradingHighest stickiness, lowest commodity sensitivity — largest single bucket 26%

Specialty / OtherFood-grade lubricants (12-16% global share), EV electrolytes, digital lubrication ~15% of EBIT 14%

The 14% specialty bucket throws an outsized ~15% of EBIT — so the terminal margin debate is really a specialty-mix-shift debate, not a base-engine-oil debate.

Country mix (revenue-weighted)

🇩🇪Germany 20.0%

🇺🇸United States 17.0%

🇨🇳China 16.4%

🇬🇧United Kingdom 7.5%

🇫🇷France 7.0%

🇮🇹Italy 6.5%

🇪🇸Spain 5.5%

🇸🇪Sweden 3.5%

🇦🇺Australia 3.5%

🌐Other (10) 13.0%

Eurozone tilt (Germany + France + Italy + Spain ≈ 39%) keeps the weighted country-risk add-on small at 0.87%. Russia = 0 (exited 2022). Iran/Hormuz risk is SUPPLIER-side (Gulf base oils), not in the revenue-weighted CRP.

Background — five things to know before the case

Context the share price doesn't carry on its face. Skim this once and the divergence ladder below stops reading as inside baseball.

Two share classes, identical cashflows, 25% price gap. FPE.DE is ordinary (voting), FPE3.DE is preference (non-voting). Both receive almost identical dividends. The preference is trading €37.52 while the ordinary trades €30 — a 25% premium on the non-voting line, the inverse of the usual pref discount. This DCF values the ordinary because identical cashflows plus a vote at a 25% discount is the cleaner trade.
Kepler is the lone Sell on the Street. Kepler Cheuvreux cut the name to Strong Sell on 1 April 2026 with PT €34, citing Iran-driven raw-material costs. Deutsche Bank, Berenberg, Barclays, UBS and JPM all carry Buy with avg PT €47.60. The consensus disagreement isn't whether FUCHS is a good business — it's how much margin Gulf base-oil inflation eats through 2027.
FUCHS missed its previous 5-year plan by 280bps. The FUCHS 2025 plan also targeted a 15% EBIT margin. It landed at 12.21%. The new FUCHS100 plan (April 2026 Capital Markets Day) targets 13-15% margin by 2031 with the same management team who missed the last one. The base case here gives them credit for stability at 11.5%, not for recovery.
The EV-transition drag on lubricants is structural, not cyclical. UBS sees global lubricant value growth slowing from ~2.6%/year today to ~0.4%/year over the next 5 years as electric vehicles eliminate engine-oil demand. Automotive on-highway is 17% of FUCHS revenue, vehicle components another 15% — roughly a third of the book is structurally shrinking in the terminal year.
Family-controlled, 24 consecutive dividend increases, net cash €151M. The Fuchs family holds 59% of the voting ordinary stock through a protective association. They've never cut the dividend in 24 years (including 2009, 2020, 2022), the Aug 2024 buyback retired 5.76% of the share count at €263M, and insider buying in 2025-26 was concentrated in the ordinary at €30-36. This is the data point that justifies setting failure probability to zero.
WACC re-corrected via β triangulation. Earlier pass used Damodaran's US Chemical Specialty subset (β_u 0.82, β_lev 0.84), giving WACC 6.56%. A correction to global (β_u 1.04, β_lev 1.06) gave WACC 7.65%, but the multi-source 5Y regression β for FPE is 0.77 (Yahoo, StockAnalysis, SimplyWallSt, FT all between 0.76 and 0.86). The 38% gap between regression and Damodaran-global triggers triangulation → trust regression. FUCHS is a niche specialty-lubricants formulator with family-stable governance and ~zero net debt — genuinely lower-beta than the broad Chemical Specialty aggregate (commodity petrochem cyclicals). Final: β 0.77, Ke 6.33%, WACC 6.22%, MoS +43.8%.

Where we diverge from the sector

Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.

Assumption

Our input

Sector median

Value impact

01 Revenue growth 10-year CAGR

~1.9% CAGR€3.56B → €4.30B by FY35

~3.5%Specialty chemicals · peers compound faster

−€4.20

02 Operating margin Target in Year 5

11.5% by Y5below FY25 actual 12.2%

12.17%Specialty chemicals, US industry standard

−€2.30

03 Sales-to-capital Reinvestment efficiency

1.7 → 1.6asset-light branded specialty

1.105Specialty chemicals, US industry standard

+€9.80

04 Terminal growth Year 10+ steady state

2.0%below EUR risk-free 2.5%

2.5%at EUR risk-free ceiling

−€1.60

05 Cost of capital WACC, 10-year average

6.22%β 0.77 (5Y regression, multi-source) · CRP 0.87% · Aaa synth

~7.65%Damodaran global re-levered would give 1.06 — triangulation triggered, regression won

+€3.85

Net effect of overrides

Overrides net +€4.45/share vs all-defaults · FUCHS is conservative on revenue, margin AND terminal growth, but the regression β (0.77) catches the structurally low-risk profile that the broad Chemical Specialty aggregate (commodity petrochem cyclicals) misses — the lower cost of capital now carries most of the value lift alongside asset-light reinvestment efficiency.

+€4.45

Our override Sector median Override adds value Override subtracts value

The story & the five claims

The 10-year story this DCF is built on, plus the five anchor claims that translate the story into model inputs.

FUCHS is the world's #1 INDEPENDENT lubricants franchise — a €3.56B specialty distributor with 12-16% global share in food-grade lubricants, an opening German EV-electrolyte plant, and a 24-year dividend streak built on family control and net cash. The market is pricing two real headwinds as if they were terminal: Gulf base-oil inflation from the 2025-26 Iran/Hormuz overhang, and the structural EV-driven slowdown of lubricant market value growth (UBS: 2.6% → 0.4%/yr). The base case isn't that either headwind resolves. It's that FUCHS compounds revenue at ~1.9%/yr to €4.3B by FY35 — bracketing UBS's 0.4% market-value floor with the €4.0-4.5B FUCHS100 ceiling — while operating margin glides DOWN from FY25's 12.2% to 11.5% by Y5 (below the FUCHS100 13-15% ambition because the same management team missed the prior plan by 280bps with the same playbook). Terminal growth pinned at 2.0%, deliberately BELOW the EUR risk-free, reflecting the transition-economy framework: the specialty franchise grows, the core engine-oil business shrinks, net compounding stalls in perpetuity. Even on those numbers, the asset-light economics (sales-to-capital 1.7 vs sector 1.1) and the Aaa balance sheet deliver €43.15 of intrinsic value against a €30 price.

CLAIM 01 Revenue compounds ~1.9% CAGR to €4.3B by FY35. €3,563M FY25 → €4,300M FY35 Brackets UBS's 0.4% market-value floor with FUCHS100's €4.0-4.5B 2031 mid-target plus an execution haircut. M&A bolt-ons offset specialty share gains in the math.

CLAIM 02 Operating margin lands at 11.5%, slightly below sector median. FY25 12.2% → Y5 11.5% Honest base post-2025 plan miss. The 16-17% era is gone (raw-material lag, commodification). FUCHS100's 13-15% target sits in the MC tail, not in the base case.

CLAIM 03 Sales-to-capital steps down 1.7 → 1.6. specialty plants come online German electrolyte plant (Sep 2024), OPET Turkey buyout, South Africa & Mexico expansions tilt the asset base. Still well above sector median 1.1.

CLAIM 04 Convergence by Year 5. margin steady-state by FY30 Mature 90-year branded specialty franchise. FUCHS100 is itself a 5-6 year plan; the margin recovery has been underway since the 2022 trough.

CLAIM 05 Terminal growth pinned at 2.0%, below EUR risk-free. transition-economy framework Specialty franchise grows, engine-oil core shrinks, net stall in perpetuity. Failure probability zero — 24-year dividend streak, net cash, family control.

Where we diverge from sell-side consensus

Margin glides DOWN, not UP. Consensus models FUCHS100 margin recovery to 13-15%. We model a slight decline from FY25 12.2% to 11.5% by Y5. The same management team missed FUCHS 2025 by 280bps using the same playbook.
Council pivoted from FPE3 pref to FPE ord. At a 25% premium on the non-voting line with identical cashflows, the cleaner trade is long ordinary. Insider family buying in 2025-26 was in the ordinary at €30-36, not the pref.
Governance haircut 0%, not 5%. Pref shares would deserve a 5% discount (no voting). On the ordinary, you hold the vote. Sub-2x asset-light economics + Aaa balance sheet + 24-year dividend streak — no further haircut.
Terminal growth below risk-free. EUR risk-free is 2.5%; we use 2.0%. Lubricant market value growth slows to 0.4%/yr per UBS — the specialty franchise grows but the engine-oil core shrinks, and the net is sub-risk-free.

Two-sided case — bear anchors

Kepler thesis: Iran/Hormuz cost squeeze persists. Q1 26 FCF guide cut to "significantly below €270M" on working-capital build from Gulf base-oil inflation. If margin retests 10-11% structurally, PT drops to €34-€39.
EV transition compresses core faster than modelled. Automotive on-highway 17% + components 15% = ~32% of revenue structurally shrinking. Faster compression collapses Y10 revenue below €4.0B.
China softness deepens. 16.4% of revenue; Suzhou is the largest APAC market. No near-term inflection visible in FY25 commentary. Continued weakness chips at 3-5% of group revenue.
FX overlay: 100bps margin sensitivity to EUR strength. ~40% of revenue is non-EUR. A 10% EUR appreciation cycle takes the FY25 base off the table. Already in the MC overlay.
Pref-ord premium collapses to parity. If the 25% premium on FPE3 normalizes, FPE ord re-rates upward on technical flow — but pref holders take the haircut. This is the case for being on the ord side of the trade.

Risks to thesis

FUCHS100 margin recovery failsHigh

Same management team missed FUCHS 2025 by 280bps. If 13-15% target slips like the prior plan, terminal margin re-rates toward 10-11% and the model breaks — PV(terminal) at 62.9% of EV amplifies any margin haircut.

EV transition compresses core fasterHigh

UBS sees lubricant value growth 2.6% → 0.4% over 5y. Automotive on-highway 17% directly exposed + vehicle components 15% indirect = ~32% of revenue. Faster-than-modelled compression collapses Y10 revenue below €4.0B.

China softness deepensMed

16.4% of revenue; Suzhou specialty plant is the largest APAC market. Continued weakness chips at 3-5% of group revenue and breaks the 1.9% Y10 CAGR thesis; no near-term inflection visible in FY25 commentary.

EUR appreciation 10%Med

~40% of revenue is non-EUR; 100bps reported margin sensitivity to a 10% EUR move with zero operational change. FY25 EBIT base may be FX-flattered from 2024 USD strength.

Iran/Hormuz raw-material persistenceMed

Q1 26 FCF guide cut to "significantly below €270M" on WC build from Gulf base-oil inflation. Kepler's load-bearing bear thesis. Structurally impaired margin (10.5% perpetual) drops PT toward €34-€39.

Pref-ord arb collapsesMed

25% pref premium is anomalous (normally pref discount). If the premium collapses to parity, FPE ord re-rates favourably — but if you're holding the pref, you take the haircut.

10-year forecast

Revenue €3.63B → €4.30B over 10y (~1.9% CAGR). Operating margin glides DOWN from FY25 actual 12.21% to target 11.50% by Y5 — no heroic recovery to the FUCHS100 13-15% ambition. FCFF holds in the €273-296M/yr band.

Monte Carlo distribution

1000 iterations randomising Y10 revenue, target margin, terminal growth and a EUR-FX overlay (~40% non-EUR revenue). P(intrinsic < market €30.00) = 0.0% — every iteration in the distribution still lands above today's price after β triangulation lowered WACC to 6.22%.

Every iteration in the 1000-path distribution still lands above today's €30 print after β triangulation — the disagreement isn't whether FUCHS ord is undervalued, but by how much (p5 €40, p95 €54).

Mean €46.08 ± €4.20/sh · P(intrinsic < market) = 0.0% · 1000 iterations.

⚠ Active model commentary: Terminal value contributes 62.9% of EV; explicit 10y discounted FCFF contributes 37.1%. Undiscounted terminal value alone is 116.5% of EV — the perpetuity stream after Y10 is bigger than the entire enterprise. This is honest model output: margin declines from 12.21% (FY25) to 11.5% by Y5 while revenue grows and reinvestment builds, so the explicit FCFF band holds at €273-296M/yr while discounting shrinks each year's PV. Terminal compounds at g=2.0% with ROC 12.88% > WACC 6.22%. If you don't believe the 11.5% terminal margin, the model breaks here.

Cost of capital build

Risk-free rate	2.50%
Mature-market ERP	4.11%
Levered β	0.77
Weighted CRP	0.87%
Cost of equity	6.33%
Pre-tax cost of debt (synth Aaa/AAA)	1.96%
D / V	~3%
WACC	6.22%
Terminal growth	2.00%
Terminal ROIC	12.88%

Full year-by-year DCF

Year	Revenue	Op mgn	EBIT	EBIT(1−t)	Reinvest	FCFF	PV
1	€3.63B	12.07%	€438M	€313M	€40M	€273M	€257M
2	€3.70B	11.93%	€441M	€315M	€41M	€275M	€242M
3	€3.77B	11.78%	€444M	€318M	€41M	€276M	€228M
4	€3.84B	11.64%	€447M	€320M	€42M	€278M	€215M
5	€3.91B	11.50%	€450M	€322M	€43M	€279M	€203M
6	€3.99B	11.50%	€459M	€327M	€46M	€280M	€191M
7	€4.06B	11.50%	€467M	€331M	€47M	€284M	€182M
8	€4.14B	11.50%	€476M	€336M	€48M	€288M	€173M
9	€4.22B	11.50%	€485M	€341M	€49M	€292M	€164M
10	€4.30B	11.50%	€495M	€346M	€50M	€296M	€156M

Methodology & flags

FCFF DCF, 10y explicit + perpetuity. Country risk premium derived from a 19-country revenue-weighted mix (Germany 20% / USA 17% / China 16.4% top-three) crossed with 2026 country CRPs, landing at 0.87%. Synthetic credit rating Aaa/AAA from a 39.5× interest-coverage ratio and a +€151M net-cash balance. Monte Carlo: 1000 iterations sampling Y10 revenue, Y10 EBIT margin, terminal growth and a EUR-FX overlay (~40% non-EUR revenue, 100bps margin sensitivity). Valuation pivoted from FPE3.DE preference to FPE.DE ordinary (voting) given the 25% pref premium.

R&D cap: OFF · Lease cap: OFF · Failure: OFF · ESO: OFF
Governance haircut: 0% applied (FPE.DE ord = voting)
Sensitivity tornado: not run · superseded by 1000-iter Monte Carlo
Cost-of-debt: synthetic Aaa/AAA (ICR €435M EBIT / €11M interest = 39.5x; net cash €151M)